{"id":"W3028527898","doi":"10.1016/j.annonc.2020.03.245","title":"144P Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Chugai Pharmaceutical; Genentech; Servier; Eisai; Daiichi-Sankyo; Daiichi Sankyo Europe; Université de Liège; Curtin University of Technology; Incyte; Gilead Sciences; FibroGen; Merck KGaA; Genomic Health; Ariad Pharmaceuticals; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; PharmaMar; Celgene; BC Cancer Agency; Centro de Investigación Biomédica en Red de Cáncer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Progression-free survival; Fulvestrant; Placebo; Breast cancer; Oncology; Cancer; Urology; Gastroenterology; Overall survival; Estrogen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001061837,0.0003098365,0.000579951,0.0002821551,0.0001625257,0.0006059916,0.0002478101,0.0003917629,0.002893876],"category_scores_gemma":[0.001196011,0.00009674697,0.001989268,0.0004921765,0.0001755417,0.0004505332,0.0004531371,0.0009895132,0.0003705556],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005138174,"about_ca_system_score_gemma":0.0004184746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00110016,"about_ca_topic_score_gemma":0.002098676,"domain_scores_codex":[0.9995443,0.0001803472,0.00004354878,0.00006097587,0.0000735835,0.00009724329],"domain_scores_gemma":[0.9992411,0.0001864522,0.0003052971,0.00002826688,0.00006337246,0.0001755021],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1949198,0.002890568,0.5995298,0.001532102,0.01015243,0.0004013572,0.0002274321,0.005310523,0.004022707,0.0005246304,0.00790087,0.1725878],"study_design_scores_gemma":[0.006426044,0.02586204,0.9509863,0.0001782897,0.005125901,0.0004800879,0.0002246888,0.003367803,0.001154325,0.0004808595,0.005649957,0.00006374057],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912443,0.002902224,0.0001279527,0.0002684452,0.0000596651,0.00005199752,0.003370429,0.00001725352,0.001957803],"genre_scores_gemma":[0.9945029,0.0007041405,0.0001399955,0.0001941301,0.00004167447,0.0001256648,0.003351075,0.000003807417,0.0009365338],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002893876,"threshold_uncertainty_score":0.009680927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05540093340937784,"score_gpt":0.357927209976405,"score_spread":0.3025262765670271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}